NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Buy
55
CVM Quote, Financials, Valuation and Earnings
Last price:
$0.71
Seasonality move
:
26.37%
Day range:
$0.66 - $0.74
52-week range:
$0.49 - $3.23
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.50x
Volume:
817.2K
Avg. volume:
845.8K
1-year change:
-73.17%
Market cap:
$46.6M
Revenue:
--
EPS (TTM):
-$0.58
Analysts' Opinion
-
Consensus RatingCEL-SCI has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, CEL-SCI has an estimated upside of 959.51% from its current price of $0.73.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.73.
Fair Value
-
According to the consensus of 0 analysts, CEL-SCI has 959.51% upside to fair value with a price target of -- per share.
CVM vs. S&P 500
-
Over the past 5 trading days, CEL-SCI has overperformed the S&P 500 by 7.93% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
CEL-SCI does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CEL-SCI has grown year-over-year revenues for 1 quarter straight. In the most recent quarter CEL-SCI reported revenues of --.
Earnings Growth
-
CEL-SCI has grown year-over-year earnings for 0 quarters straight. In the most recent quarter CEL-SCI reported earnings per share of -$0.14.
Enterprise value:
46.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-2.41x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$35.6M | -$33M | -$27.7M | -$8.2M | -$6.7M | |
| EBITDA | -$31.3M | -$29M | -$23.7M | -$7.2M | -$5.7M | |
| Diluted EPS | -$0.85 | -$0.77 | -$0.58 | -$0.19 | -$0.14 | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $22.7M | $49.7M | $31M | $7.7M | $3.5M | |
| Total Assets | $42M | $79.6M | $56.9M | $32.3M | $24.1M | |
| Current Liabilities | $4.7M | $5.2M | $4M | $5.3M | $5.5M | |
| Total Liabilities | $23M | $19.8M | $18.2M | $17.5M | $15.6M | |
| Total Equity | $19M | $59.8M | $38.7M | $14.8M | $8.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$18.1M | -$22.7M | -$19M | -$5.7M | -$4.6M | |
| Cash From Investing | $10.1M | -$378K | -$98.7K | -$196.9K | -$23.5K | |
| Cash From Financing | $148.3K | $156.9K | $14.4M | $951.6K | -$322.3K | |
| Free Cash Flow | -$19.2M | -$23.1M | -$19.1M | -$5.9M | -$4.6M | |
CVM
Sector
Market Cap
$46.6M
$43.9M
Price % of 52-Week High
22.6%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-73.17%
-29.11%
Beta (5-Year)
0.593
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$0.70
200-day SMA
Sell
Level
$1.21
Bollinger Bands (100)
Sell
Level
0.71 - 1.15
Chaikin Money Flow
Sell
Level
-447.7M
20-day SMA
Buy
Level
$0.64
Relative Strength Index (RSI14)
Buy
Level
53.13
ADX Line
Buy
Level
13.78
Williams %R
Neutral
Level
-60.4905
50-day SMA
Sell
Level
$0.74
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
276.8M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Stock Forecast FAQ
In the current month, CVM has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CVM average analyst price target in the past 3 months is --.
-
Where Will CEL-SCI Stock Be In 1 Year?
According to analysts, the consensus estimate is that CEL-SCI share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About CEL-SCI?
Analysts are divided on their view about CEL-SCI share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CEL-SCI is a Sell and believe this share price will drop from its current level to --.
-
What Is CEL-SCI's Price Target?
The price target for CEL-SCI over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CVM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CEL-SCI is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CVM?
You can purchase shares of CEL-SCI via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CEL-SCI shares.
-
What Is The CEL-SCI Share Price Today?
CEL-SCI was last trading at $0.71 per share. This represents the most recent stock quote for CEL-SCI. Yesterday, CEL-SCI closed at $0.73 per share.
-
How To Buy CEL-SCI Stock Online?
In order to purchase CEL-SCI stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 4.46% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 10.25% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.77% over the past day.
